^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Angiopoietin 2 inhibitor

    Related drugs:
    9d
    GLIA-MAC: Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy (clinicaltrials.gov)
    P=N/A, N=60, Completed, Federico II University
    New trial
    |
    Eylea (aflibercept intravitreal)
    13d
    Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Osijek University Hospital
    New trial
    1m
    MAGIC: Safety and Efficacy of Faricimab in Patients With NPDR (clinicaltrials.gov)
    P2, N=179, Completed, Greater Houston Retina Research | Active, not recruiting --> Completed
    Trial completion
    1m
    JADE: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 (clinicaltrials.gov)
    P1, N=164, Completed, Ollin Biosciences, Inc.
    New P1 trial
    1m
    A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P1, N=93, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Mar 2027 --> Nov 2026
    Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)
    2ms
    Two initial faricimab loading doses in treatment-naive neovascular AMD (2024-514408-15-00)
    P4, N=50, Active, not recruiting, Medical University Of Graz | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P1, N=93, Not yet recruiting, Genentech, Inc.
    New P1 trial
    2ms
    Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) (clinicaltrials.gov)
    P=N/A, N=1000, Recruiting, Hoffmann-La Roche | Active, not recruiting --> Recruiting
    Enrollment open • HEOR • Real-world evidence
    3ms
    Diabetic Macular Edema (DME) Patient Response to Faricimab and Associated Aqueous Humor Proteomic Differences Pre- and Post-Treatment (ChiCTR2500113982)
    P=N/A, N=154, Not yet recruiting, Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital
    New trial
    4ms
    VOYAGER: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (clinicaltrials.gov)
    P=N/A, N=6000, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2026 --> Mar 2027
    Enrollment closed • Trial primary completion date • Real-world evidence
    |
    Lucentis (ranibizumab)
    4ms
    SHort Of Pace - Heart Failure (SHOP-HF) (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Fundación para la Investigación del Hospital Clínico de Valencia | Not yet recruiting --> Recruiting
    Enrollment open
    |
    L1-10